Alexion And BridgeBio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine

Monday, September 9, 2019 1 min read

Key Takeaway: Alexion And BridgeBio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine

Full Press Release Details

Alexion And BridgeBio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine.